Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - SETTLEMENT AGREEMENT WITH VIRAL GENETICS INC. - Immunotech Laboratories, Inc. | viral_genetics-pressrelease.htm |
SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Nevada | 333-57514 | 95-4834274 | ||
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification Number) |
116 West Stocker Street, Glendale, California | 91202 | |
(Address of principal executive offices) | (Zip Code) |
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
In March 2012, Immunotech Laboratories, Inc. and collectively the Zhabilov Group, entered into a binding Release
and Settlement Agreement with Viral Genetics Inc. and collectively the Viral Group and its principals that was approved by the
court. The Settlement ends the almost 5-year-old lawsuit between the parties, dismissing all claims without admission of liability
by any party.
The Company’s HIV/AIDS technology and the Zhabilov Group’s cancer therapeutics and detection technology intellectual
property portfolio have grown considerably in these last five years. As a result, both the Company and the Zhabilov Group are now
free to pursue possible partnerships and joint ventures at a much higher level that better reflect the value of the work.
Item 9.01 Financial Statements and Exhibits
Exhibit
Number Description
99.1 Press Release
IMMUNOTECH LABORATORIES, INC. |
|||||
Date: May 17, 2012 | By: | /s/ Ara Ghanime | |||
Ara Ghanime | |||||
President | |||||